Essilor International SA (ESSI.PA)

Essilor International SA (ESSI.PA) Trading on MT5 at XM

At XM we offer Essilor International SA (ESSI.PA) stocks as cash CFDs. Our cash CFDs stocks are undated transactions that aim to replicate the cash price of the underlying stock, and so they are adjusted for any relevant corporate actions.

Open a Demo Account
Open an Account

Risk warning: FX and CFD trading involves a high risk of loss.

About Essilor International SA (ESSI.PA) Trading

Founded in 1849, Essilor International SA is a leading French company in the medical industry. The company specializes in the research, design, manufacturing and sales of a wide range of products related to ophthalmic optics (e.g. corrective lenses, sun and reading glasses, and other ophthalmic equipment and instruments). The company is a CAC 40 stock market index component, and its stock is traded on Euronext.

Trading Conditions

Margin requirement 10 %
Spreads as low as 0.27
Symbols Essilor
Description Essilor International SA
Min. Price Fluctuation 0.01000
Value of Minimum Price Fluctuation EUR 0.1
Value of 1 lot 10 Shares
Min/Max Trade Size 1/84
Swap Value in Margin Currency Long -2.58 %
Swap Value in Margin Currency Short -3.42 %
Limit and Stop Levels** 0.05
Total Volume Limit (per client)*** 833
Trading time (server time) 10:10-18:25 (GMT +2)
** Min. level for placing pending orders at a current market price.

*** Note that the maximum trading volume for Essilor per client is 833 lots. This limit will be reviewed on a daily basis and updated according to the value of the instrument.

How to Start Trading Essilor International SA (ESSI.PA)?

Step 1

Open an XM Real Account


Step 2

Download and login to the MT5 platform


Step 3

Double-click on Essilor International SA (ESSI.PA) from the “Market Watch” to open an order for this instrument.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.